PPI | C57Bl/6J | Vehicle and MK-801 controls, 15–17; others, 9–10 | BQCA (s.c.) + antipsychotics (i.p.) | MK-801 overall | F(1, 343) = 315.3 | <0.001 |
| | | | BQCA alone | None | |
| | | | BQCA + haloperidol | | |
| | | | BQCA effect | F(4, 174) = 4.3 | 0.002 |
| | | | Haloperidol effect | F(1, 174) = 45.0 | <0.001 |
| | | | BQCA × haloperidol interaction | F(4, 174) = 3.3 | 0.013 |
| | | | BQCA + clozapine | | |
| | | | BQCA effect | F(4, 165) = 2.7 | 0.032 |
| | | | Clozapine effect | F(1, 165) = 31.6 | <0.001 |
| | | | BQCA + aripiprazole | | |
| | | | BQCA effect | F(4, 160) = 2.7 | 0.031 |
| | | | Aripiprazole effect | F(1, 160) = 24.6 | <0.001 |
| | | | Prepulses × BQCA × Aripiprazole × MK-801 interaction | F(4, 320) = 4.5 | 0.002 |
Y-maze | C57Bl/6J | 10–13 | BQCA (s.c.) + antipsychotics (i.p.) | BQCA alone | | |
| | | | Arm effect | F(1, 59) = 17.2 | <0.001 |
| | | | Arm × MK-801 effect | F(1, 59) = 9.7 | 0.003 |
| | | | BQCA + haloperidol | | |
| | | | Arm effect | F(1, 124) = 8.4 | 0.005 |
| | | | Arm × MK-801 effect | F(1, 124) = 6.4 | 0.012 |
| | | | BQCA + clozapine | | |
| | | | Arm effect | F(1, 123) = 13.4 | <0.001 |
| | | | Arm × MK-801 effect | F(1, 123) = 5.1 | 0.026 |
| | | | Arm × BQCA effect | F(2, 123) = 3.5 | 0.034 |
| | | | BQCA + aripiprazole | | |
| | | | Arm effect | F(1, 132) = 18.0 | <0.001 |
| | | | Arm × MK-801 effect | F(1, 132) = 8.6 | 0.004 |
PPI | M1+/+ mice (C57Bl/6 Ntac background) | Vehicle and MK-801 controls, 15–16; others, 8–9 | BQCA (i.p.) + clozapine (i.p.) | M1+/+ mice | | |
| M1−/− mice (C57Bl/6 Ntac background) | Vehicle and MK-801 controls, 13–15; others, 8 | | MK-801 effect | F(1, 67) = 29.0 | <0.001 |
| | | | BQCA effect | F(2, 67) = 3.2 | 0.046 |
| | | | Clozapine effect | F(1, 67) = 8.3 | 0.005 |
| | | | M1−/− mice | | |
| | | | MK-801 effect | F(1, 61) = 26.2 | <0.001 |